Clinical Trials
3 trialsNCT02530320 2024-11-22
Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
Grupo Español de Investigación en Neurooncología
Phase 2 Completed
NCT02255461 2021-03-02
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Pediatric Brain Tumor Consortium
Phase 1 Terminated
NCT01227434 2015-07-17
PD0332991
University of California, San Francisco
Phase 2 Terminated